Queen's Medical Centre, Nottingham, UK
National University of Malaysia, Kuala Lumpur, Malaysia.
Clin Med (Lond). 2022 Sep;22(5):449-454. doi: 10.7861/clinmed.2021-0597.
Acute stroke is the leading cause of disability in the UK and a leading cause of mortality worldwide. The majority of patients with ischaemic stroke present with minor deficits or transient ischaemic attack (TIA), and are often first seen by patient-facing clinicians. Urgent evaluation and treatment are important as many patients are at high risk of major vascular events and death within hours to days after the index event. This narrative review summarises the evidence on four antiplatelet treatments for non-cardioembolic stroke prevention: aspirin, clopidogrel, dipyridamole and ticagrelor. Each of these drugs has a unique mechanism and has been tested as a single agent or in combination. Aspirin, when given early is beneficial and short-term treatment with aspirin and clopidogrel has been shown to be more effective in high-risk TIA / minor stroke. This review concludes by highlighting gaps in evidence, including scope for future trials that could potentially change clinical practice.
急性脑卒中是英国的主要致残原因,也是全球范围内的主要致死原因之一。大多数缺血性脑卒中患者仅有轻微的缺陷或短暂性脑缺血发作(TIA),且通常首先由面向患者的临床医生进行诊治。紧急评估和治疗非常重要,因为许多患者在指数事件发生后的数小时至数天内存在发生重大血管事件和死亡的高风险。本综述总结了四项抗血小板药物治疗非心源性卒中和预防卒中的证据:阿司匹林、氯吡格雷、双嘧达莫和替格瑞洛。这些药物中的每一种都有其独特的作用机制,且已分别作为单一药物或联合药物进行了测试。早期使用阿司匹林有益,且阿司匹林和氯吡格雷联合短期治疗已被证明对高危 TIA/小卒中更有效。本综述最后强调了证据中的空白,包括未来可能改变临床实践的试验范围。